DrugDashboards

Potassium Citrate

Potassium Citrate · POTASSIUM CITRATE 5 meq/1 · Tablet, Extended Release · Actavis Pharma, Inc.

NDC 00591-2682-00 · 7825 TABLET, EXTENDED RELEASE in 1 DRUM · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 68382-0536-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$0.2757per unit
middle half $0.2103–$0.5007 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.2757
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for potassium citrate (oral solid) in the next 90 days

sole-source market · price up 1% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $94.21 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Xywav and Xyrem

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—

Shortage history

  • Planned discontinuation — Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)Jul 17, 2025
  • Planned discontinuation — Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)Jul 17, 2025
  • Planned discontinuation — Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)Jul 17, 2025

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Potassium Citrate (Tablet, Extended Release)

LabelerStrengthFirst seenLast seen
Actavis Pharma, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 3, 2026
Actavis Pharma, Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 3, 2026
American Health PackagingPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, IncPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, IncPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, IncPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Mission Pharmacal CompanyPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Mission Pharmacal CompanyPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.POTASSIUM CITRATE 540 mg/1Jul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.POTASSIUM CITRATE 1080 mg/1Jul 15, 2026Sep 2, 2026
XLCare Pharmaceuticals, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
XLCare Pharmaceuticals, Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
XLCare Pharmaceuticals, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals (USA) Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals (USA) Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals (USA) Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Aug 31, 2026
Remedyrepack Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Potassium Citrate — NDC 00591-2682-00," retrieved September 3, 2026, https://drugdashboards.com/drug/00591268200.

Free to cite with attribution — see how the data is put together.